Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Butyrate for Cognitive Function in Schizophrenia
NCT03010865Phase 3Withdrawn
- Sponsor
- Shanghai Mental Health Center
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium butyrate in schizophrenia and cognitive impairment, sponsored by Shanghai Mental Health Center. Primary endpoint: MATRICS Battery at 12 weeks. Planned start Jun 2017; status: withdrawn.
02
Drugs
sodium butyrate
03
Conditions
schizophreniacognitive impairment
Beyond the preview
Go deeper on NCT03010865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010865.